Related by context. All words. (Click for frequent words.) 79 Investigational Device Exemption IDE 74 exemption IDE 72 Premarket Approval PMA 69 liver resection surgeries 69 Market Approval PMA 68 IND Investigational New 67 ENLIGHT 67 ORBIT II 66 Fast Track Designation 66 Premarket Approval 65 Anturol TM 65 Drug Eluting Stent System 65 Biologic License Application BLA 65 Premarket Approval Application 65 Humanitarian Device Exemption 65 Marketing Authorization Application 65 FDA Investigational Device 65 FDA Approvable Letter 65 Fast Track Status 65 Cellegesic 64 Marketing Authorization Application MAA 64 CIP TRAMADOL ER 64 IDE Investigational Device Exemption 64 Biologics License Application 64 Government Qualifying Therapeutic 64 Completes Patient Enrollment 64 Application BLA 64 Orphan Drug Status 64 PMA submission 63 OLpur TM H2H 63 FOLOTYN ® 63 BLA submission 63 Augment Injectable 63 Oral Calcitonin 63 granted Ortec 63 Phase #b/#a clinical 63 Pivotal Trial 63 GRAS notification 63 Dupuytren Contracture 63 Investigational 63 rolling Biologics License 63 Special Protocol Assessment 63 Orphan Drug status 63 Pivotal Clinical Trial 63 Pivotal Phase III 63 sNDA submission 62 Biologics License Application BLA 62 IND submission 62 GATTEX TM 62 BLA filing 62 Initiates Enrollment 62 PrevOnco 62 PROTECT AF 62 NDA Submission 62 supplemental Biologics License Application 62 Clinical Trial Application 62 Clinical Trials Agreement 62 Files Investigational 62 Orphan Status 62 Exemption IDE approval 62 Zenvia ™ 62 REPEL CV 62 PROPEL trial 62 Trobalt 62 Marketing Approval PMA 62 MAGE A3 ASCI 61 PROVENGE sipuleucel T 61 Fast Track designations 61 Phase III Clinical Trial 61 Augment Bone Graft 61 GTC recombinant form 61 Initiates Phase II 61 miconazole Lauriad R 61 Expanded Indication 61 Luveniq 61 Alair System 61 pseudobulbar affect PBA 61 Granted Orphan Drug 61 intravesical infusion therapy 61 VIVITROL ® 61 Phase Ib IIa 61 Files IND 61 MIST II 61 vapreotide acetate 61 PROVENGE ® 61 REVIVE Diabetes 61 pralatrexate injection folate analogue 61 Biologic License Application 61 FDA Accepts 61 OAB overactive bladder 61 Phase IIIb clinical 61 Biological License Application 61 CryoSeal FS System 61 MelaFind R 61 lucinactant 61 Fast Track designation 61 NUEDEXTA ™ 61 Vascular Grafts 61 Orphan Drug designation 61 Begins Dosing 61 intravitreal insert 61 Marketing Authorisation Application 61 phase IIb clinical 61 OMAPRO ™ 60 CRMD# 60 Treatment IND 60 phase IIb III 60 Receives Orphan Drug Designation 60 IND Filing 60 unique alkylating agent 60 Expedited Review 60 Completes Enrollment 60 Marketing Authorization 60 autologous cellular immunotherapy 60 Rhucin ® recombinant 60 Drug Submission 60 Zenvia Phase III 60 Civacir 60 ADVANCE PD 60 IONSYS TM 60 PMA Supplement 60 Iluvien ® 60 Supplemental Biologics License Application 60 Phase III psoriasis 60 ZEGERID Chewable Tablets 60 GTC recombinant human 60 label Lipofen R 60 Phase lll 60 trastuzumab DM1 T DM1 60 Patient Enrollment 60 randomized controlled multicenter 60 Phase IIb III 60 Ganite ® 60 Oracea TM 60 PROGENSA R 60 Phase IIa clinical trials 60 Crofelemer budesonide foam 60 BRILINTA 60 confirmatory Phase 3 60 mesylate tablets approved 60 APEX AMI trial 60 EOquin TM 59 Submits Investigational 59 Patent Covering 59 LUVENIQ 59 Contrave NDA 59 PANVAC VF 59 highly purified pasteurized 59 FDA Orphan Drug 59 Accelerated Partial Breast Irradiation 59 Phase 2b Clinical Trial 59 vinorelbine emulsion 59 urethral bulking agent 59 treat atrial flutter 59 IV acetaminophen 59 R lenalidomide 59 Receives Milestone Payment 59 prGCD 59 personalized cellular immunotherapy 59 pivotal bioequivalence 59 TM Drug Eluting 59 Application MAA 59 EVIZON TM 59 vertebral augmentation 59 Phase III Pivotal 59 ThermoDox R 59 orphan designation 59 Clinical Trial Evaluating 59 Meets Primary Endpoint 59 Metformin GR 59 Dyloject TM 59 zolpidem tartrate sublingual tablet 59 phase IIb trial 59 TAXUS Element Stent System 59 Phase IIB 59 TM pralatrexate injection 59 Phase III multicenter 59 markets HP Acthar 59 ongoing Phase 1b 59 sBLA 59 Phase IIb Trial 59 Initiates Clinical 59 Cardioxyl Pharmaceuticals 59 CoreValve System 59 oral ridaforolimus 59 Inc. OTCBB SYBD 59 PDX pralatrexate 59 orally bioavailable compound 59 Receives CE Marking 59 hoFH 59 multicenter Phase III 59 Accelerated Approval 59 Randomized Phase II 59 Taro Receives 59 assigned PDUFA 59 eprodisate KIACTA TM 59 Combination REOLYSIN R 59 Horizant ™ 59 Somatuline R Autogel R 59 Submits Supplemental 59 SYCREST 59 Submits Response 59 Phase III confirmatory 59 symbol ABII 59 severe hypercholesterolemia 59 Arzerra ofatumumab 59 ATryn R 59 CORTOSS 58 Ganite R 58 Loramyc ™ 58 XL# anticancer compounds 58 Surgical Adhesive 58 INSPIRE Trial Phase III 58 Besivance 58 Gentamicin Surgical Implant 58 Initiate Phase 58 delivers fluocinolone acetonide FA 58 Fibrillex TM 58 IL# PE#QQR 58 Impax ANDA 58 NEBIDO R 58 VALSTAR 58 EvaMist TM 58 EmbraceAC 58 dasatinib Sprycel ® 58 JOULFERON 58 By JAMAAL ABDUL 58 Entereg R 58 Approvable Letter 58 ATryn ® 58 IND Application 58 Phase 2b kidney transplant 58 OvaRex ® MAb 58 phase Ib clinical 58 Dose Ranging Study 58 Submits Biologics License Application 58 Soliris TM eculizumab 58 Marketing Authorisation 58 Pivotal Phase 58 RNAi Therapeutic 58 arsenic trioxide injection 58 thorough QT 58 POSIDUR TM 58 Complete Response 58 candidate REP# 58 Vitrasert R 58 nasal calcitonin product 58 Receives Approvable Letter 58 Diabetic Macular Edema 58 Cloretazine ® 58 Discovery Project QTDP 58 ProEthic Pharmaceuticals 58 HepaGam B 58 Nabi HB Intravenous 58 Pivotal Study 58 BioGlue R 58 product platforms AZX# 58 Arzerra TM 58 LEVADEX ™ 58 antibiotic candidate Ramoplanin 58 FACTIVE R gemifloxacin 58 phase III isavuconazole 58 FIRAZYR 58 Initiates Phase III 58 Phase IIIb 58 hypoxia activated prodrug 58 Ceplene ® histamine dihydrochloride 58 balsalazide disodium 58 Computed Tomography Laser Mammography 58 Soliris eculizumab 58 E1 INT TM 58 COMFORT II 58 Omigard 58 MAb therapy 58 UPLYSO 58 Phase 2a Trial 58 Sanvar R 58 Patient Enrolment 58 cerebral oximeter available 58 eSVS MESH 58 NasdaqGM SPPI 58 Phase III Psoriasis 58 designated HVTN 58 Anti CD# Antibody 58 indiplon capsules 58 Awarded Qualifying Therapeutic 58 severe gastroparesis 58 dose escalation clinical 58 Phase IIb Clinical Trial 58 refractory chronic lymphocytic 58 Phase 2a clinical trials 58 ENTEREG ® 58 Romiplostim 58 Initiated Phase 58 IMPELLA R 58 candidate XP# 58 Zelrix 58 Submits IND 58 FDA Complete Response 58 Receives Orphan Drug 58 novel histone deacetylase 58 CERVARIX R 58 Prodarsan R 58 Pegloticase 58 GEM OS1 58 First Patient Enrolled 58 oxymorphone ER 58 NDA submission 58 Act PDUFA date 58 PrevOnco ™ 58 FDA Clearance 58 GeoVax AIDS vaccine 58 sNDAs 58 immunosuppressive compound 58 INTELLITEMP ® 58 Tarceva TM 58 Approvable letter 58 FDA approvable letter 57 New Drug IND 57 Successfully Completes Phase 57 Icatibant 57 balsalazide tablet 57 Personalized Immunotherapy 57 alvimopan 57 Mutual Recognition Procedure 57 website http:/www.celsion.com 57 Cardiac Cryoablation System 57 Glycopyrrolate 57 IgG1 monoclonal antibody 57 Abstral ® 57 Orphan Drug designations 57 Phase IIb kidney transplant 57 Angiox ® 57 Prospective Randomized 57 Neovasc Reducer 57 TRANSDUR ™ 57 R bendamustine hydrochloride 57 REGENERX BIOPHARMACEUTICALS INC. 57 Phase 1b clinical trials 57 RANK Ligand inhibitor 57 Orphan Designation 57 Embolic Protection Device 57 MAA submission 57 Orphan Drug Designation 57 MOVIPREP R 57 Cintredekin besudotox 57 Presents Positive 57 Receives Fast Track 57 Mylan Receives Approval 57 recurrent metastatic ovarian cancer 57 PROMUS TM 57 Enrolls First 57 BRIM3 57 BRIM2 57 Long Term Efficacy 57 Augment TM 57 MONOVISC 57 Acute Attacks 57 Elagolix 57 Iluvien TM 57 SUMAVEL 57 Testosterone MDTS ® 57 treat chronic sinusitis 57 New Drug Application 57 Matrix Phase 2b 57 Aflibercept 57 investigational 57 Complete Response letter 57 Voraxaze 57 supplemental biologics 57 Nasdaq DVAX 57 Inc. OTCBB VODG 57 Levoleucovorin 57 visit www.dobimedical.com 57 Methylnaltrexone 57 Levacor 57 Phase IIIb study 57 Release Capsules 57 Marketing Authorization Applications 57 hyaluronidase enzyme 57 Vascular Closure Device 57 successfully commercialize Iluvien 57 faropenem medoxomil 57 Accelerated Assessment 57 Linjeta TM 57 Silodosin 57 confirmatory Phase III 57 MEND CABG II 57 ThermoDox ® 57 Tramiprosate ALZHEMED TM 57 PROMACTA CARES 57 branded Rectogesic 57 Barr ANDA 57 placebo controlled Phase III 57 symbol AVXL 57 Qualifying Therapeutic Discovery 57 phase IIa clinical 57 rALLy clinical trial 57 VEGFR2 inhibitor 57 Severe Sepsis 57 MelaFind ® 57 Combidex 57 Oracea R 57 ferumoxytol Injection 57 Fibrin Pad 57 HDL Selective Delipidation 57 Neo Urinary Conduit 57 Genasense R 57 submit Biologics License 57 APEX PD 57 Investigational Device 57 Phase Ib study 57 randomized controlled Phase 57 Investigational Treatment 57 CIP Fenofibrate 57 Resubmission 57 Hematide ™ 57 compound ISA# 57 VISICOL R 57 vernakalant hydrochloride 57 BEMA ® 57 NYSE Amex PTN 57 TLK# 57 EVICEL 57 multicenter clinical 57 BioNumerik 57 COSIRA trial 57 Demonstrates Sustained 57 TAXUS Element Paclitaxel Eluting 57 adjuvant GIST 57 Phase IIa Clinical Trial 57 application sNDA 57 Oxycyte ® 57 Endeavor Drug Eluting 57 PFO migraine 57 Raptiva R 57 ARIXTRA R 57 ADVEXIN p# therapy 57 BioSTAR ® 57 Emezine 57 ELADUR ™ 57 PNP inhibitor 57 Zingo TM 57 Virulizin R 57 Advanced Melanoma 57 Prochymal TM 57 AFRS TM 57 Phase 2a clinical 57 CLIA waiver 57 Phase 2b clinical 57 Ranolazine 57 proprietary transdermal patch 57 OTCBB APCSF 57 ALVESCO R 57 FDA Approval 57 Dacogen injection 57 Argatroban 57 Premarket Notification 57 Adhesion Barrier 57 ibuprofen Injection 57 LensAR Laser System 57 liposomal formulation 57 methylnaltrexone bromide 57 ALN VSP Phase 57 Metformin HCl 57 Ixempra 57 Medidur TM FA 57 investigational humanized monoclonal antibody 57 exclusive sublicense 57 histamine dihydrochloride 57 European Sepsis Trial 57 Orapred ODT 57 Announces Tentative Approval 57 Bone Graft 57 EGRIFTA TM 57 RELISTOR ® 57 known teratogen substance 57 Hedgehog Pathway Inhibitor 57 submitted supplemental Biologics 57 acetonide FA 57 Phase III Trial 57 ™ Paclitaxel Eluting 57 LEVADEX TM 57 Submits NDA 56 PROMUS Element Stent 56 TRANSDUR ® 56 SinuNase TM 56 Intermezzo ® NDA 56 k premarket 56 TELINTRA R 56 Biomerix Corporation 56 STEDESA 56 Subpart E 56 Orathecin 56 Alvesco R 56 MEK Inhibitor 56 Cetrorelix pamoate 56 herpetic keratitis 56 OMP designation 56 Study Evaluating 56 PROMACTA ® 56 GLP1 INT TM 56 registrational Phase 56 novel emulsion formulation 56 Acetavance TM 56 Testosterone Gel 56 investigational pharmacologically unique 56 Initiates Clinical Trial 56 CIMZIA r 56 candidate deforolimus 56 ENTB 56 Nasdaq HALO 56 ULTRASE 56 Tanespimycin 56 SUCCEED trial 56 PDUFA Date 56 Phase #b/#a 56 Dementia Related Psychosis 56 miconazole MBT 56 SURFAXIN 56 HuMax TAC 56 anticancer compound 56 Monovalent Vaccine 56 GENTAMICIN SURGICAL IMPLANT 56 Drug Application 56 Marketing Authorisation Application MAA 56 Hsp# Inhibitor 56 Kit CD# positive 56 Entereg TM 56 corticotropin injection 56 visit www.regenbio.com 56 TRACON Pharmaceuticals Inc. 56 TORISEL 56 pediatric exclusivity 56 Pirfenidone 56 dependent kinase inhibitor 56 received CE Conformite 56 ZBx 56 CIP ISOTRETINOIN 56 MyVax R 56 Randomized Phase 56 BR.# 56 solifenacin succinate 56 website www.celsion.com 56 metastatic castrate resistant 56 ZEFTERA ™ 56 Regulatory Approval 56 recombinant PSMA vaccine 56 Cellegesic TM nitroglycerin ointment 56 DC Bead 56 Phase III ThermoDox 56 Achieves Primary Endpoint 56 RX ACCULINK 56 submitted Biologics License 56 Prodarsan 56 SPL# Gel vaginal microbicide 56 Ofatumumab 56 Manja Bouman CEO 56 LymphoStat B TM 56 Phase Ib II 56 Valortim TM 56 ISO Vorin TM 56 LEUKINE 56 KRYSTEXXA TM pegloticase 56 Frova ® 56 GATTEX ™ 56 DermTech International 56 dirucotide MBP# 56 multicenter Phase II 56 REVLIMID lenalidomide 56 ACUROX 56 BEXXAR 56 PROMUS Element Stent System 56 relapsed refractory multiple myeloma 56 Allovectin 7 r 56 generation purine nucleoside 56 IMPACT DCM 56 Fortical ® 56 interferon gamma 1b 56 oxybutynin ATD TM 56 WorldHeart Announces 56 Phase 2b Trial 56 Phase III clinical 56 ATPace TM 56 OrCel R 56 ARRY # 56 Liprotamase 56 Commences Phase 56 EXPLORE Xa 56 Market Authorization Application 56 investigational pan BCR 56 Clinical Trial Results 56 opioid induced bowel dysfunction 56 individualized cellular immunotherapy 56 TYZEKA 56 Esbriet pirfenidone 56 dextromethorphan quinidine 56 Pre IND 56 cyclobenzaprine hydrochloride extended 56 acyclovir Lauriad R 56 ThermoDox ® clinical 56 XIAFLEX ™ 56 LibiGel ® 56 Durezol TM 56 dihydrochloride Tablets 56 catheter occlusion 56 FavId 56 Plenaxis TM 56 pediatric glioma 56 Phase 1a clinical 56 pivotal Phase III 56 induced macular edema 56 Zenpep 56 rilonacept 56 Zenvia TM 56 Centralized Procedure 56 Panzem R 56 Anturol ® 56 Initiate Phase III 56 registrational trial 56 PREOS R 56 candidate AQ4N 56 NasdaqGM NTEC today 56 memantine HCl 56 prospective multicenter randomized 56 Augment Injectable Bone Graft 56 Flutiform ™ 56 Plicera 56 Bradmer Pharmaceuticals 56 oral methylnaltrexone 56 lorcaserin NDA 56 transgenically produced product 56 Arimoclomol 56 CORTOSS Bone Augmentation Material 56 XIAFLEX ® 56 received CE Marking 56 product BioThrax ® 56 NEUMUNE 56 novel trazodone formulation 56 sodium Injection 56 StaphVAX R 56 Receives FDA Clearance 56 drug ISA# 56 Genasense ® oblimersen 56 Subpart H 56 Silenor ® doxepin 56 Ceflatonin 56 TRANSDUR Sufentanil 56 gabapentin enacarbil 56 fluvoxamine maleate 56 injectable enzyme 56 NPS NPS Pharmaceuticals 56 CTLM ® 56 RECOTHROM R 56 TachoSil 56 OTCQX QRXPY 56 Junovan TM 56 Phase III pivotal 56 Loramyc TM 56 NM# [001] 56 Oracea ® 56 GATTEX ® 56 Genasense ® 56 telavancin NDA 56 Genasense R oblimersen 56 Cardium Therapeutics TM 56 Belimumab 56 Xcytrin R 55 exocrine pancreatic insufficiency EPI 55 NYSE Amex RPC 55 Neuromodulation System 55 PD2i Cardiac Analyzer 55 Neurodex TM 55 Refractory Peripheral T 55 Augment ™ 55 CINTREDEKIN BESUDOTOX 55 ATryn ® GTC recombinant 55 budesonide MMX Phase III 55 perifosine KRX 55 initiated Phase Ib 55 BioSTAR R 55 ALTROPANE R 55 ABL inhibitor 55 sNDA 55 Lenocta TM 55 Optical Biopsy System 55 Phase 1b trial 55 MEND CABG 55 Tectin TM 55 mGluR2 positive 55 VCRT 55 FDA APPROVES 55 Ceftobiprole 55 Pafuramidine 55 registrational 55 AIR CF1 55 CE Marked 55 ENDEAVOR IV 55 virus HCV protease inhibitor 55 LibiGel Phase III 55 Gamunex C 55 Phase III HEAT 55 Solzira TM 55 Trial Evaluating 55 FDA Accelerated Approval 55 Commence Phase 55 TRELSTAR R 55 Acute Decompensated Heart Failure 55 Australian Therapeutic Goods 55 Phase 1b Clinical Trial 55 multicenter Phase 55 Primera Bioscience 55 DASISION 55 evaluating mipomersen 55 Bioral ® 55 fosbretabulin 55 Desvenlafaxine Succinate 55 Prestara 55 methylnaltrexone 55 investigational antiplatelet agent 55 drug pipeline TAFA# 55 Ohr Pharmaceutical Inc. 55 TRISENOX ® 55 Shonin approval 55 Dabigatran etexilate 55 structure infections ABSSSI 55 Completes Patient Enrolment 55 Conditional Approval 55 PEGINTRON TM 55 ADP receptor antagonist 55 novel oral anticoagulant 55 CB2 selective receptor agonist 55 Bazedoxifene 55 Drug Eluting Stent 55 ZEGERID Powder 55 Vicor anticipates 55 Somatuline R Depot 55 Clevudine 55 Randomized Double Blind 55 phase IIa 55 sorafenib tablets 55 oral prodrug 55 HepeX B TM 55 BioGlue ® 55 Exclusive License 55 KRYSTEXXA TM 55 Raptiva ® 55 TKB# 55 Biologics Licensing 55 refractory Hodgkin lymphoma 55 randomized Phase IIb 55 ISTODAX 55 BEMA Granisetron 55 Receives CE 55 Initiate Phase II 55 Abstract Accepted 55 topically applied SEPA 55 OvaRex R 55 Thrombin topical Recombinant 55 Initiate Clinical Trial 55 rasagiline tablets 55 mitogen activated ERK kinase 55 single injection viscosupplement 55 REG1 Anticoagulation System 55 Kamada AAT 55 compound CIP FENOFIBRATE 55 Deferiprone 55 implantable VeriChip TM 55 IIa trial 55 Empatic TM 55 Romidepsin 55 VITAL Trial 55 SANVAR 55 LUNESTA TM 55 LHRH antagonist 55 k Premarket Notification 55 PROSTASCINT R 55 OmniWave 55 Simulect 55 LUCASSIN 55 Cotavance 55 iloprost Inhalation Solution 55 Urocidin TM 55 pixantrone NDA 55 RAPTIVA 55 Receives Marketing Authorization 55 intravenous iclaprim 55 Telavancin 55 ZEGERID Capsules 55 Chronic Idiopathic Constipation 55 Demonstrates Significant 55 JAK2 Inhibitor 55 immunotherapeutic vaccine 55 Phase 2a 55 Announces FDA Clearance 55 Bioral Amphotericin B 55 ANCHOR trial 55 SNT MC# 55 cutaneous T 55 Demonstrates Positive 55 Completes Dosing 55 SNS# T 55 Liberte TM 55 BrachySil TM 55 phase Ib 55 TRX1 55 ZALBIN 55 Tamibarotene 55 Drug Administration FDA Oncologic 55 QLT# 55 Qualified Therapeutic Discovery 55 Risperidone Oral Solution 55 XOMA 3AB 55 cetrorelix pamoate 55 Traficet EN 55 phase IIb study 55 Aloxi Injection 55 sumatriptan injection 55 pharmacologic stress agent 55 Orthopedic Advisory Panel 55 placebo controlled Phase 55 Daclizumab 55 Xcellerated T Cells 55 oral nucleoside analogue 55 Junovan 55 CALGB # [002] 55 II Clinical Trial 55 Curaxin CBLC# 55 treatment naive genotype 55 Resten NG 55 IIb clinical trial 55 Friedreich Ataxia FRDA 55 Inc. NASDAQ NEOL 55 intravenous formulation 55 REMOXY POSIDUR ELADUR 55 mesylate tablets 55 Biologics License Applications 55 human C1 inhibitor 55 Glatiramer Acetate 55 BLOOM DM 55 PERLANE 55 Vimpat R 55 Tezampanel 55 myelodysplastic myeloproliferative diseases 55 Reports Preclinical Data 55 CONBRIZA 55 Proellex TM 55 EndoBarrier ™ 55 Eniluracil 55 Product Designation 55 MERLIN TIMI 55 forodesine 55 investigational atypical antipsychotic 55 topical non steroidal 55 PRECISE Trial 55 Onco TCS 55 Surfaxin lucinactant 55 Phase Ib clinical 55 IMPDH inhibitor 55 XIENCE V Stent System 55 DURIN TM 55 taliglucerase alfa 55 PDUFA Prescription Drug 55 Initiates Phase 2b 55 Fondaparinux 55 MKC# 55 IMPACT IMmunotherapy 55 Phase IIa trial 55 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 55 Cinryze TM 55 Lucanix R 55 Phase IIb clinical 55 Tibotec Therapeutics division 55 Drug Applications INDs 55 oral rivaroxaban 55 QNEXA ® 55 Confirmatory Phase 55 Google Permissions 55 testosterone gel LibiGel 55 reslizumab 55 Milestone Payment From 55 Receives Conditional 55 AVASTIN 55 Kynapid 55 Phase Ib 55 GENERIC SILDENAFIL SOFT Generic 55 Oral Spray 55 Prostate AdenoCarcinoma Treatment 55 Amrubicin 55 Esbriet ® 55 Aurexis 55 ACOMPLIA R 55 Ridaforolimus 55 ZEFTERA TM Zevtera TM 55 Development OOPD 55 TSX SHQ 55 OrCel ® 55 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 55 GLP1 agonist 55 Rotarix R 55 Nicotine Conjugate Vaccine 55 RESTORE CLI trial 55 ONGLYZA ™ 55 Retacrit 55 Genasense oblimersen sodium Injection 55 Ceflatonin ® 55 icatibant 54 HP Acthar Gel repository 54 Plenaxis R 54 ospemifene 54 NASDAQ TARG 54 cinacalcet HCl 54 Phase 1b clinical 54 lomitapide 54 Metastatic Melanoma 54 Nasdaq PPHM 54 Clinical Study Shows 54 Efficacy Results 54 HDAC Inhibitor 54 FlexStent ® 54 Degarelix 54 Restanza TM 54 selective A2A adenosine receptor 54 Multiple Ascending Dose 54 Project QTDP program 54 Patients Treated With 54 designated Restanza 54 Severe VOD 54 Inc. Nasdaq CVTX 54 DEXILANT 54 Keppra XR TM 54 thrombin component 54 blinded randomized placebo controlled 54 sumatriptan DosePro 54 Sapacitabine 54 Exalgo TM 54 PRECISE trial 54 visit http:/www.mannkindcorp.com 54 ENRICH trial 54 including eniluracil ADH 54 Androxal TM 54 PLK1 SNALP 54 Reloxin ® 54 Tyrosine Kinase Inhibitor 54 Zor Pharmaceuticals 54 Receives Complete Response 54 Lamictal ODT 54 PRN FDA Approves 54 Intermezzo R 54 OsseoFix 54 Teflaro 54 zileuton CR 54 HydroFix 54 tramiprosate Alzhemed TM 54 PHX# 54 PIX# trial 54 Onalta ™ 54 Topline Results 54 Issued Patent 54 Augment ™ Bone Graft 54 GRALISE 54 IMA# 54 lexidronam injection 54 Hypoactive Sexual Desire Disorder 54 ANDA submission 54 octreotide implant 54 Evoltra TM 54 Nasdaq CYCC Nasdaq CYCCP 54 Composite Coatings 54 NEBIDO 54 T Pred 54 Tolvaptan 54 ZYBRESTAT fosbretabulin 54 OctoPlus licensed 54 Ampligen r 54 Angiox R 54 Pennsaid R 54 LUMINATE 54 Gets FDA Clearance 54 systemic immunosuppressive drugs 54 SUPPRELIN R LA 54 Phase IIa trials 54 ID NCT# 54 ENDEAVOR III 54 Ozurdex 54 lorcaserin Phase 54 Fanapt ™ 54 TSX PWE FRANKFURT 54 NYSE Amex RGN 54 Pralatrexate 54 Shelf Prospectus dated 54 Dacetuzumab 54 huC# DM4 54 Onrigin 54 dose escalation phase 54 APTIVUS ritonavir 54 orphan medicinal product 54 R sipuleucel T 54 identifier NCT#